Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. https://www.ncbi.nlm.nih.gov/pubmed/31695838 背…

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). https://www.ncbi.nlm.nih.gov/pubmed/29045553 背景：分…

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study. https://www.ncbi.nlm.nih.gov/pubmed/32318871 目的：REVELでは、進行した非小細胞肺癌（aNSCLC）の患者と腫瘍の侵攻…

Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L). https://www.ncbi.nlm.nih.gov/pubmed/32066647 abstract ・Chemo→ICI→Chemo vs Chemo→C…

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. https://www.ncbi.nlm.nih.gov/pubmed/30642552 目的：免疫チェックポイント阻害剤（ICI）は、進行した非…

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of p…